Sponsor of the Day:
Jerkmate
https://www.thepharmanavigator.com/news/abbvie-remegen-sign-exclusive-licensing-agreement-for-novel-bispecific-antibody
AbbVie, RemeGen Sign Exclusive Licensing Agreement for Novel Bispecific Antibody — The Pharma...
Jan 14, 2026 - The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across...
sign exclusivelicensing agreementbispecific antibodyabbvienovel
https://www.genengnews.com/multimedia/webinars/data-driven-strategies-for-addressing-bispecific-antibody-purification-challenges/
Data-Driven Strategies for Addressing Bispecific Antibody Purification Challenges
Mar 25, 2026 - In this GEN webinar, Joshua Orchard, a purification applications scientist with extensive experience in downstream process development of various modalities,...
data driven strategiesbispecific antibodyaddressingpurificationchallenges
https://www.latimes.com/doctors-scientists/medicine/cancer/story/bispecific-antibodies-vs-car-t-cell-therapy
Bispecific Antibodies vs CAR T-Cell Therapy in Oncology - Los Angeles Times
Apr 24, 2026 - A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T cells.
oncology los angelesvs carcell therapybispecificantibodies
https://wellington-partners.com/immatics-achieves-clinical-proof-of-concept-of-its-next-generation-tcr-bispecific-tcer-pipeline-with-data-on-ima402-prame-and-ima401-magea4-8-and-announces-next-development-steps/
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline...
Nov 24, 2025 - ALCESTER, England and BEVERLY, Massachusetts, 23 June 2021: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader
next generationimmaticsachievesclinicalproof
https://www.koreabiomed.com/news/articleView.html?idxno=31445
[AACR 2026] ABL Bio advances bispecific ADCs, eyes dual-payload shift Bio Article - KBR
SAN DIEGO, Calif. -- Hong Sook / Korea Biomedical Review correspondent -- ABL Bio presented preclinical data for its bispecific antibody-drug conjugate (ADC)...
aacr 2026ablbioadvancesbispecific
https://www.biopharmadive.com/news/pd1-vegf-inhibitors-cancer-immunotherapy-bispecific-startups/741231/
Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda | BioPharma Dive
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.
pd 1cancer drugsbiopharma diveblockingvegf
https://www.flcancer.com/bispecific-therapy/
Bispecific Therapy treatments - helping your body fight cancer
Bispecific antibody drugs are among the growing number of immunotherapies offering promising new options for treating certain types of cancer.
fight cancerbispecifictherapytreatmentshelping
https://www.nature.com/articles/s41573-024-00896-6?error=cookies_not_supported&code=e8d0859a-fe48-4a58-8e77-588f5480bc43
The present and future of bispecific antibodies for cancer therapy | Nature Reviews Drug Discovery
Mar 6, 2024 - Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic applications that cannot be achieved using conventional IgG-based...
nature reviews drugcancer therapypresentfuturebispecific
https://www.hcahealthcare.co.uk/about-us/news-and-press-releases/first-lung-cancer-patient-treated-at-hca-uk-hospital-with-pioneering-bispecific-antibody-therapy
Pioneering bispecific antibody therapy | HCA UK
HCA UK’s The Harborne Hospital in Birmingham has become the first facility in the West Midlands to treat a lung cancer patient using bispecific antibody...
bispecific antibodyhca ukpioneeringtherapy